All In Biotech

Drug Trial Radar · NCT06563895

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)

Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 587 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

587

Planned (sponsor's estimate)

Start

May 12, 2025

Primary completion

Oct 2031

Study completion Dec 2032

Sponsor

Sponsor type
Industry
First posted
Aug 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid that may no longer be sufficiently cleared by the body. This type of ATTR is known as wild-type ATTR (ATTRwt). The other way occurs when a person inherits a defective TTR gene that causes the TTR protein to spontaneously fall apart. This form of the disease is known as variant ATTR (ATTRv) and can be detected in adults by a genetic test of their TTR gene before they age. Amyloid build-up in the heart causes the heart wall to become thick and stiff and can result in heart failure and even death. Accumulation of TTR amyloid in the heart is known as transthyretin amyloid cardiomyopathy or ATTR-CM. Amyloid can also deposit in the nerve tissues leading to nerve problems. Accumulation of TTR in the nerves is known as transthyretin amyloid polyneuropathy or ATTR-PN. Acoramidis is an experimental drug designed to bind tightly to TTR in the blood and stabilize its structure, so it does not form the harmful amyloid plaques that can cause damage to organs. This study is intended to determine if treatment with acoramidis in participants with ATTRv who have not yet developed any symptoms of disease can prevent or delay the development of ATTR-CM or ATTR-PN disease. If adults with an inherited defective TTR gene are treated early before any of the symptoms of disease have developed, it may be possible to delay the onset or prevent the disease entirely.

Conditions

  • Amyloidosis
  • Amyloid Cardiomyopathy
  • Transthyretin Amyloidosis
  • Cardiomyopathies
  • Heart Diseases
  • Polyneuropathies

Interventions

  • AcoramidisDrug

    TTR stabilizer administered orally twice daily (BID)

  • Placebo oral tabletDrug

    Non-active control administered orally twice daily (BID)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to development of ATTR (ATTR-CM or ATTR-PN, whichever occurs first; centrally adjudicated)Time frame: Since randomization up to approximately 7 years or until the study is declared over

Locations

104 sites in 24 countries. Site status is shown where the registry gives one.

  • University of California, San Diego (UCSD) - Medical Center

    La Jolla, California · Recruiting

  • University of California, Los Angeles (UCLA) - David Geffen School of Medicine

    Los Angeles, California · Recruiting

  • University of California, San Francisco (UCSF)

    San Francisco, California · Recruiting

  • Stanford University

    Stanford, California · Recruiting

  • University of Colorado Anschutz

    Aurora, Colorado · Recruiting

  • Yale University School of Medicine - Section of Cardiology

    New Haven, Connecticut · Recruiting

  • MedStar Washington Hospital Center - MedStar Heart and Vascular Institute

    Washington D.C., District of Columbia · Recruiting

  • Mayo Clinic - Jacksonville

    Jacksonville, Florida · Recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • Cleveland Clinic Florida

    Weston, Florida · Recruiting

  • Emory University School of Medicine

    Atlanta, Georgia · Recruiting

  • John H. Stroger, Jr. Hospital of Cook County

    Chicago, Illinois · Recruiting

  • University of Chicago - Medical Center

    Chicago, Illinois · Recruiting

  • University of Maryland Medical Center

    Baltimore, Maryland · Recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • Boston University (BU) School of Medicine

    Boston, Massachusetts · Recruiting

  • Henry Ford Health System

    Detroit, Michigan · Recruiting

  • Mayo Clinic - Rochester

    Rochester, Minnesota · Recruiting

  • St. Luke's Hospital of Kansas City

    Kansas City, Missouri · Recruiting

  • Washington University in St. Louis

    St Louis, Missouri · Recruiting

  • Rutgers-Robert Wood Johnson Medical School

    New Brunswick, New Jersey · Recruiting

  • New York University (NYU) School of Medicine - Langone Medical Center

    New York, New York · Recruiting

  • Mount Sinai Hospital

    New York, New York · Recruiting

  • Columbia University Medical Center

    New York, New York · Recruiting

  • Laurelton Heart Specialists

    Rosedale, New York · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

  • Penn Presbyterian Medical Center

    Philadelphia, Pennsylvania · Recruiting

  • University of Pittsburgh Medical Center, Presbyterian Hospital

    Pittsburgh, Pennsylvania · Recruiting

  • Medical University of South Carolina (MUSC)

    Charleston, South Carolina · Recruiting

  • Prisma Health Cancer Institute

    Greenville, South Carolina · Recruiting

  • National Neuromuscular Research Institute

    Austin, Texas · Recruiting

  • University of Texas Southwestern

    Dallas, Texas · Recruiting

  • University of Utah

    Salt Lake City, Utah · Recruiting

  • INOVA Fairfax Hospital

    Falls Church, Virginia · Recruiting

  • Virginia Commonwealth University

    Richmond, Virginia · Recruiting

  • University of Washington Medical Center

    Seattle, Washington · Recruiting

Showing 40 of 104 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.